MXCT

MaxCyte, Inc._January 12, 2026 0001287098false00012870982026-01-122026-01-12 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549 ​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): January 12, 2026 ​

​ MaxCyte, Inc. (Exact name of registrant as specified in its charter) ​ ​

​

​

​

​

Delaware ​ ​ ​ 001-40674 ​ ​ ​ 52-2210438

(State or other jurisdiction of incorporation) ​ (Commission File Number) ​ (IRS Employer Identification No.)

​ 9713 Key West Avenue, Suite 400 Rockville, Maryland 20850 (Address of principal executive offices, including zip code) ​ (301) 944-1700 (Registrant’s telephone number, including area code) ​ N/A (Former name or former address, if changed since last report) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of each class ​ ​ ​ Trading Symbol(s) ​ ​ ​ Name of each exchange on which registered

Common Stock, $0.01 par value ​

MXCT

​ The Nasdaq Stock Market LLC

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company    ☒ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​

Item 2.02. Results of Operations and Financial Condition. ​ On January 12, 2026, MaxCyte, Inc. (the “Company”) issued a press release announcing preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. ​ In accordance with General Instructions B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing. ​ Item 9.01. Financial Statements and Exhibits. ​ (d) Exhibits ​ Exhibit Number ​ ​ ​ Exhibit Description

​ ​ ​

99.1 ​ Press Release, dated January 12, 2026

104 ​ Cover Page Interactive Data (embedded within the Inline XBRL document)

​ ​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

​ MaxCyte, Inc.

​ ​

Dated: January 12, 2026 By: /s/ Douglas Swirsky

​ ​ Douglas Swirsky

​ ​ Chief Financial Officer

​ ​ ​

MaxCyte, Inc._November 12, 2025 0001287098false00012870982025-11-122025-11-12 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549 ​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): November 12, 2025 ​

​ MaxCyte, Inc. (Exact name of registrant as specified in its charter) ​ ​

​

​

​

​

Delaware

001-40674

52-2210438

(State or other jurisdiction of incorporation) ​ (Commission File Number) ​ (IRS Employer Identification No.)

​ 9713 Key West Avenue, Suite 400 Rockville, Maryland 20850 (Address of principal executive offices, including zip code) ​ (301) 944-1700 (Registrant’s telephone number, including area code) ​ N/A (Former name or former address, if changed since last report) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value ​

MXCT

​ The Nasdaq Stock Market LLC

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company    ☒ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​

Item 2.02. Results of Operations and Financial Condition. ​ On November 12, 2025, MaxCyte, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. ​ The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing. ​ ​ ​ Item 7.01. Regulation FD Disclosure. ​ On November 12, 2025, the Company posted an updated corporate presentation, which the Company may use from time to time in communications or conferences, to its website at https://investors.maxcyte.com.  A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. ​ The information in this Current Report on Form 8-K, including Exhibit 99.2 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing. ​ Item 9.01. Financial Statements and Exhibits. ​ (d) Exhibits ​ Exhibit Number

Exhibit Description

​ ​ ​

99.1 ​ Press Release, dated November 12, 2025

99.2 ​ Corporate Presentation, dated November 2025

104 ​ Cover Page Interactive Data (embedded within the Inline XBRL document)

​ ​ ​ ​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

​ MaxCyte, Inc.

​ ​

Dated: November 12, 2025 By: /s/ Douglas Swirsky

​ ​ Douglas Swirsky

​ ​ Chief Financial Officer

​ ​ ​

MaxCyte, Inc._November 5, 2025 0001287098false00012870982025-11-052025-11-05 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549 ​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): November 5, 2025 ​

​ MaxCyte, Inc. (Exact name of registrant as specified in its charter) ​ ​

​

​

​

​

Delaware

001-40674

52-2210438

(State or other jurisdiction of incorporation) ​ (Commission File Number) ​ (IRS Employer Identification No.)

​ 9713 Key West Avenue, Suite 400 Rockville, Maryland 20850 (Address of principal executive offices, including zip code) ​ (301) 944-1700 (Registrant’s telephone number, including area code) ​ N/A (Former name or former address, if changed since last report) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value ​

MXCT

​ The Nasdaq Stock Market LLC

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company    ☒ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​

Item 2.02. Results of Operations and Financial Condition. ​ On November 5, 2025, MaxCyte, Inc. (the “Company”) issued a press release announcing preliminary unaudited financial results for the quarter ended September 30, 2025 and reiterating its full year 2025 revenue guidance. A copy of this press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. ​ The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing. ​ Item 9.01. Financial Statements and Exhibits. ​ (d) Exhibits ​

Exhibit Number

Exhibit Description

​ ​ ​

99.1 ​ Press Release, dated November 5, 2025

104 ​ Cover Page Interactive Data (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

​ MaxCyte, Inc.

​ ​

Dated: November 5, 2025 By: /s/ Douglas Swirsky

​ ​ Douglas Swirsky

​ ​ Chief Financial Officer

​ ​ ​